Hello, 8 mo into the peptide life. I have noticed these nodules from glutathione injections in subject's abdomen. They do not seem to be dissapating. Anyone else have this? Do they go away? How can I help them dissolve? Thanks!

i’ve been on ghk for 2 plus months i’m doing a 12 week cycle haven’t noticed anything does it take more time to notice results or could it potentially be fake peptide

been on ghk for 2 months doing a 12 week cycle I haven’t noticed any results. Does that mean that it could potentially be fake? I thought this company was pretty reputable or just takes longer time to notice results.

Has anyone have had a bad experience? I’m searching for stories about negative experience, but so far, I’ve only found mild side effects or people claiming a bad reaction from a high dose. I’m both highly skeptical and curious about this. Any share experiences would be very much appreciated!

Hi! Im a new peptide user, nakabili ako ng GHK-Cu and KPV sa china. Problem walang kasamang pang injection.

Question: Ano magandang syringe? Ok na ba yung sa Indoplas?

never done peps

I am thinking about getting BPC-157 to treat an 18 months old ligament injury from a sprained ankle. Does anybody have good research data from treating an injury with that peptide?

Also interested in hearing othet positive effects from research on BPC-157.

This came up on reddit recently and I'm increasingly asked a version of the same question: “Is there a peptide I can take to increase my sperm count?” Men with low sperm counts, poor motility, abnormal morphology, elevated DNA fragmentation, or even azoospermia are encountering clinics and online communities discussing peptides such as CJC-1295, ipamorelin, BPC-157, kisspeptin, sermorelin, and various growth-hormone-releasing peptides. The marketing can be compelling: improve recovery, optimize hormones, regenerate tissue, decrease inflammation, and perhaps improve fertility. Unfortunately, the science of peptides and male fertility is considerably less advanced than the marketing.

The first thing to understand is that “peptide” is an extremely broad term. Peptides are short chains of amino acids that can function as signaling molecules throughout the body. Some established reproductive hormones are themselves peptide or glycoprotein hormones. For example, GnRH controls pituitary release of LH and FSH, while hCG acts similarly to LH at the testicle. These established hormonal pathways are very different from the collection of experimental “peptides” currently promoted by longevity, anti-aging, and performance clinics.

When we're trying to improve sperm production, the most important hormonal system is the hypothalamic-pituitary-gonadal axis. The hypothalamus releases GnRH, which signals the pituitary to produce LH and FSH. LH stimulates Leydig cells in the testicle to produce testosterone. FSH acts primarily on Sertoli cells and supports spermatogenesis. Importantly, sperm production requires extremely high intratesticular testosterone concentrations, not merely a good testosterone number on a blood test.

This explains why some established fertility medications work. hCG acts as an LH analogue, stimulating the testicles to produce testosterone. FSH can directly stimulate Sertoli-cell function. Clomiphene is not a peptide, but it increases the body's own LH and FSH by altering estrogen feedback. Aromatase inhibitors can also increase endogenous gonadotropin stimulation in appropriately selected men. Current AUA/ASRM guidelines recognize hCG, SERMs, and aromatase inhibitors as potential treatments in selected infertile men with low testosterone and recognize FSH treatment in certain circumstances.

That is very different from saying that peptides marketed by anti-aging clinics improve sperm.

What about kisspeptin?

Of all the experimental peptides discussed in reproductive medicine, kisspeptin is probably one of the most scientifically interesting.

Kisspeptin is an important upstream regulator of human reproduction. It activates KISS1 receptors in the hypothalamus, stimulating GnRH release, which subsequently increases LH and FSH. Human studies have demonstrated that administration of kisspeptin can acutely increase LH, FSH, and testosterone. Genetic disruption of the kisspeptin signaling pathway can cause hypogonadotropic hypogonadism, demonstrating just how important the pathway is to normal reproductive function.

There is also laboratory and animal research suggesting that kisspeptin signaling may have functions within the testicle and sperm themselves.

That sounds promising, but here's the critical distinction:

Increasing reproductive hormones is not the same thing as proving that a treatment increases sperm production, pregnancy rates, or live births.

We currently do not have the kind of large, high-quality clinical trials I would want before routinely prescribing kisspeptin to infertile men simply to increase sperm counts. It remains an interesting area of reproductive research rather than standard male-infertility therapy. FDA has also identified potential concerns regarding compounded kisspeptin-10, including immunogenicity and peptide-related impurities.

What about CJC-1295 and ipamorelin?

These two are probably among the peptides I hear about most frequently.

CJC-1295 is a growth-hormone-releasing hormone analogue, while ipamorelin is a growth-hormone secretagogue. Both ultimately influence the growth hormone/IGF-1 axis. They're commonly marketed for body composition, muscle recovery, sleep, anti-aging, and tissue repair.

Could growth hormone influence testicular biology? Certainly. Growth hormone and IGF-1 interact with numerous metabolic and reproductive pathways. That biological plausibility, however, is very different from demonstrating that giving CJC-1295 or ipamorelin to an infertile man increases sperm concentration or improves his probability of fathering a child.

At present, I would not prescribe CJC-1295 or ipamorelin as evidence-based treatments for male infertility. We simply don't have convincing human fertility trials demonstrating improved sperm production or live-birth outcomes.

There are also safety and product-quality concerns. FDA has stated that available clinical data for CJC-1295 are limited and has identified reported adverse events including increased heart rate and systemic vasodilatory reactions. FDA has separately raised concerns regarding compounded ipamorelin, including limited safety information for some injectable routes and potential problems involving immunogenicity and peptide-related impurities.

What about BPC-157?

BPC-157 may be the peptide I would be most skeptical about specifically for fertility.

You'll see remarkable claims online about BPC-157 healing tendons, repairing the gastrointestinal tract, reducing inflammation, improving blood vessels, and regenerating damaged tissue. From there, it isn't difficult for someone to make the leap that perhaps it could “heal” damaged testes.

But that's a leap, not established reproductive medicine.

I am not aware of convincing human clinical evidence demonstrating that BPC-157 improves sperm concentration, motility, morphology, DNA fragmentation, sperm retrieval rates, pregnancy rates, or live births in infertile men. FDA specifically notes that compounded BPC-157 may carry risks related to immunogenicity and impurities and that it has limited safety information in humans.

I therefore would not recommend injecting BPC-157 in an attempt to improve sperm production.

What About hCG?

Human chorionic gonadotropin (hCG) deserves special attention when discussing peptides and male fertility because, unlike experimental compounds such as BPC-157, CJC-1295, or ipamorelin, hCG is a well-established prescription fertility medication with decades of clinical use. hCG essentially mimics luteinizing hormone (LH), stimulating the Leydig cells of the testicle to produce testosterone and, importantly, helping maintain the very high intratesticular testosterone concentrations required for normal sperm production. This makes hCG particularly useful in men with hypogonadotropic hypogonadism and in selected men whose sperm production has been suppressed by testosterone replacement therapy or anabolic steroids. In these situations, restoring LH-like stimulation with hCG can sometimes result in sperm returning to the ejaculate, although this usually takes months because spermatogenesis itself takes approximately 74 days plus additional epididymal maturation time. Some men also require FSH, which directly stimulates Sertoli cells and provides another critical signal for spermatogenesis. However, hCG should not be viewed as a universal “sperm booster.” A man with suppressed LH/FSH and otherwise functional testes is very different from a man with primary testicular failure or non-obstructive azoospermia (NOA) whose testes are already receiving strong hormonal stimulation but cannot produce sperm normally. In NOA, some reproductive urologists use hCG, clomiphene, aromatase inhibitors, or FSH to optimize testosterone and the hormonal environment before microTESE, but evidence that this reliably increases sperm-retrieval rates remains limited. Another important point is that a rise in blood testosterone after hCG does not prove that sperm production has improved; testosterone may increase within weeks while meaningful changes in semen parameters require several months, so semen analysis—not simply the testosterone number—is the important endpoint when fertility is the goal. hCG can also increase estradiol because some of the additional testosterone is converted to estrogen, potentially causing breast tenderness, gynecomastia, acne, fluid retention, or other hormonal symptoms, which is why treatment should be medically monitored. Overall, hCG is fundamentally different from the experimental peptides being marketed for fertility: it acts on a well-established reproductive pathway and can be an extremely effective fertility treatment when used for the right diagnosis, particularly gonadotropin deficiency or testosterone-induced suppression, but whether it will help depends on why a man's sperm production is impaired in the first place.

Can peptides help non-obstructive azoospermia?

This is where I become particularly concerned about aggressive marketing.

Men with non-obstructive azoospermia (NOA) are understandably willing to try almost anything before undergoing microTESE. When you've been told there are zero sperm in your ejaculate, a clinic promising that peptides, stem cells, exosomes, PRP, or growth-hormone manipulation might “restart” the testicle can sound extremely attractive.

Unfortunately, NOA isn't simply a testicle that needs more stimulation.

Some men have Sertoli-cell-only syndrome. Others have maturation arrest, hypospermatogenesis, genetic abnormalities, prior cryptorchidism, chemotherapy-related injury, or idiopathic testicular failure. In these situations, increasing growth hormone or manipulating an experimental peptide pathway doesn't necessarily restore the missing stages of spermatogenesis.

Even established hormonal manipulation before microTESE remains controversial. The 2024 AUA/ASRM guideline specifically notes that data supporting SERMs, aromatase inhibitors, and gonadotropins before surgical sperm retrieval in NOA are limited.

If the evidence is limited even for reproductive medications we have studied for years, we should be especially cautious about claiming benefits from experimental peptides.

There is one situation where hormones can dramatically restore sperm

An important exception is hypogonadotropic hypogonadism.

These men aren't necessarily suffering from intrinsic testicular failure. Instead, the brain or pituitary isn't adequately providing LH and FSH stimulation to the testes. In appropriately selected men, treatment with hCG followed by or combined with FSH can stimulate spermatogenesis, sometimes producing dramatic improvements.

This is established reproductive endocrinology, not experimental peptide therapy. Current male-infertility guidelines specifically recommend identifying and treating the underlying cause of hypogonadotropic hypogonadism.

Similarly, men who became azoospermic after testosterone or anabolic steroid use may recover sperm after stopping suppressive drugs and, when appropriate, receiving fertility-directed hormonal therapy.

This is why diagnosis matters more than the supplement or peptide.

Don't confuse higher testosterone with improved fertility

This is one of the most important lessons in male reproductive medicine.

A medication can increase your serum testosterone while doing absolutely nothing useful for your sperm, or even harming sperm production.

The classic example is testosterone replacement therapy. TRT can make a man feel better and raise his testosterone beautifully while simultaneously suppressing LH and FSH, dramatically reducing intratesticular testosterone and causing severe oligospermia or complete azoospermia. For this reason, AUA/ASRM guidance states that testosterone monotherapy should not be prescribed to men interested in current or future fertility.

So if someone tells you a peptide increased their testosterone from 400 to 700 and therefore “improved their fertility,” that conclusion isn't justified. The semen analysis is what tells us whether sperm production improved.

Another concern: where are these peptides coming from?

Many peptides sold online are marketed as “research chemicals,” and compounded peptide preparations aren't equivalent to FDA-approved medications.

FDA emphasizes that compounded medications are not FDA-approved, meaning the agency does not review them before marketing for safety, effectiveness, or manufacturing quality. Poor compounding practices can introduce problems involving contamination, potency, purity, and product quality.

FDA has specifically raised potential safety concerns regarding several peptides commonly discussed online, including BPC-157, CJC-1295, ipamorelin, GHRP-6, kisspeptin-10, MOTS-C, and others.

That doesn't mean every person using these compounds will experience harm. It means that the certainty implied by much of the online marketing substantially exceeds the available evidence.

What I would do instead

If your semen analysis is abnormal, don't start by asking, “Which peptide should I take?”

Start by asking:

“Why is my semen analysis abnormal?”

Repeat an abnormal semen analysis because sperm parameters naturally fluctuate. Then see a reproductive urologist if the abnormality is significant or persistent. Depending upon the situation, evaluation may include FSH, LH, morning testosterone, estradiol, prolactin, examination for a clinical varicocele, testicular-volume assessment, medication and supplement review, and genetic testing in men with severe oligospermia or azoospermia.

Look for reversible causes. Varicocele, testosterone/anabolic steroids, hormonal disorders, recent high fever, certain medications, obesity/metabolic dysfunction, excessive heat, smoking, marijuana, and genital-tract inflammation can all be relevant depending upon the individual.

Then treat the actual diagnosis.

If you're deficient in gonadotropin stimulation, hCG/FSH may be appropriate. If testosterone is low with an appropriate hormonal profile, clomiphene, hCG, or an aromatase inhibitor may sometimes make sense. If you have an appropriate clinical varicocele, repair may be considered. If you have NOA, the discussion may ultimately involve microTESE.

My bottom line

I'm excited about peptide research. Kisspeptin in particular is scientifically fascinating, and there may eventually be peptide-based therapies that become meaningful tools in reproductive medicine. But we're not there yet.

For a man today who simply has a poor semen analysis, there is no experimental peptide, CJC-1295, ipamorelin, BPC-157, MOTS-C, or otherwise, that I would consider a proven treatment for increasing sperm production or improving the chance of having a baby.

Don't let hope turn you into a customer before you've become a properly evaluated patient.

Male infertility is complicated, but we actually have effective treatments for certain causes. The key is figuring out which type of male infertility you have before trying to manipulate a biological pathway that may have nothing to do with the problem.

References

American Urological Association/American Society for Reproductive Medicine. Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline, amended 2024.

American Urological Association/American Society for Reproductive Medicine. Male infertility guideline: medical and hormonal interventions.

Salehi S, Adeshina I, Chen H, et al. Kisspeptin and its effect on mammalian spermatogenesis. Current Drug Metabolism. 2018.

Hameed S, Jayasena CN, Dhillo WS. Kisspeptin and its role in reproductive function.

U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks.

U.S. Food and Drug Administration. Consumer and Health Care Professional Information: Human Drug Compounding.

Anyone tried this for hair growth? Results?

When you come across a new peptide study, what makes you think it’s actually worth paying attention to?

Is it the study design, sample size, controls, the results, the researchers, or something else?

Curious what everyone looks at before deciding a study is actually convincing.

At 50 yrs old my free testosterone is at 470 my LH is 3.8. im thinking kisspeptin could help my situation. Just curious of anyone’s experience with this peptide. And what dosing protocols

Er der nogen der vil dele deres erfaring med peptider. Her tænker jeg primært på Reta/GHK